Friday, 23 July 2021

Biomar reaches an agreement for the transfer of its production unit with the multinational 4D Pharma for 6 million euros

 Biomar Microbial Technologies, based in León, has formalized a transfer agreement for its microbial fermentation plant with the multinational 4D Pharma. Biomar, a biotechnological company based on natural products of marine origin, has closed the operation for 6 million euros.

As a consequence of this agreement, the production plant of the Leonese company will become 4D Pharma León. The operation is ratified after 18 months of collaboration between the two companies and will allow Biomar to boost its current business lines. 4D wanted to highlight the technical excellence, facilities and experience of the Biomar team to translate its research programs through clinical development and compliance with production requirements. The joint work has demonstrated the suitability of the facilities, which is why 4D made the decision to acquire the biomass production assets.

Regarding human resources, 13 current Biomar employees will be integrated into 4D Pharma León, with the expectation that 6 new workers will be hired within six months. From 4D they have highlighted the importance of having a relationship that is not dependent on external suppliers to obtain their product in relation to clinical and development programs.

This operation is excellent news for León and its area of ​​influence, as it consolidates Biomar's role as a benchmark in the biotechnology sector, while guaranteeing and developing its catalytic role in the environment. The Leonese law firm BGyC lawyers, led by Máximo Barrientos, has provided legal advice for the operation by Biomar. For its part, Ética Patrimonios EAFI, a company specialized in operations in the biotechnology sector, is Biomar's corporate advisor.

4D Pharma, based in Leeds, United Kingdom, is a leading company in the discovery and development of live biotherapies for the treatment of different pathologies. In this operation, it has been agreed to pay 2 million euros in cash and 1 million euros through the issuance of 82,349 shares, while the rest, 3 million euros, will be paid in cash based on the achievement of GMP certification for production of live biotherapeutic products at the León facilities.

Biomar, based in the León technology park, was founded in 1996 focused on the research of marine microorganisms and their use in the pharmaceutical industry, bioenergy and food production. In recent years the growth of the company has been based fundamentally on the application of its collections to the discovery and development of new biopesticides. Since 2001, it begins to expand its technologies in microbial fermentation, which allows it to provide services in this field, while expanding its production capacity of up to 3,000 liters in 2010.

No comments:

Post a Comment